Franklin Genomic Advancements ETF (HELX)
HELX is an actively managed ETF by Franklin Templeton. HELX launched on Feb 25, 2020 and has a 0.50% expense ratio.
ETF Info
ISIN | US35473P5200 |
---|---|
CUSIP | 35473P520 |
Issuer | Franklin Templeton |
Inception Date | Feb 25, 2020 |
Region | Developed Markets (Broad) |
Category | Health & Biotech Equities, Actively Managed |
Index Tracked | No Index (Active) |
Asset Class | Equity |
Asset Class Size | Multi-Cap |
Asset Class Style | Growth |
Expense Ratio
The Franklin Genomic Advancements ETF has a high expense ratio of 0.50%, indicating higher-than-average management fees.
Share Price Chart
Loading data...
Compare to other instruments
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Franklin Genomic Advancements ETF, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Returns By Period
Franklin Genomic Advancements ETF had a return of 7.51% year-to-date (YTD) and 9.21% in the last 12 months.
Period | Return | Benchmark |
---|---|---|
Year-To-Date | 7.51% | 10.16% |
1 month | -0.07% | 3.47% |
6 months | 15.58% | 22.20% |
1 year | 9.21% | 30.45% |
5 years (annualized) | N/A | 13.16% |
10 years (annualized) | N/A | 10.89% |
Monthly Returns Heatmap
Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
2024 | -2.26% | 7.99% | ||||||||||
2023 | -1.45% | -7.95% | -10.04% | 9.31% | 9.36% |
Risk-Adjusted Performance
Risk-Adjusted Performance Indicators
This table presents risk-adjusted performance metrics for Franklin Genomic Advancements ETF (HELX) and compares them with a selected benchmark (^GSPC). These performance indicators assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Sharpe ratio | Sortino ratio | Omega ratio | Calmar ratio | Ulcer Index | |
---|---|---|---|---|---|
Franklin Genomic Advancements ETF | 0.61 | ||||
S&P 500 | 2.79 |
Dividends
Dividend History
Franklin Genomic Advancements ETF granted a 0.00% dividend yield in the last twelve months. The annual payout for that period amounted to $0.00 per share.
Period | TTM | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Dividend | $0.00 | $0.00 | $0.00 | $0.12 | $0.05 |
Dividend yield | 0.00% | 0.00% | 0.00% | 0.24% | 0.12% |
Monthly Dividends
The table displays the monthly dividend distributions for Franklin Genomic Advancements ETF. The dividends shown in the table have been adjusted to account for any splits that may have occurred.
Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
2024 | $0.00 | $0.00 | ||||||||||
2023 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
2022 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
2021 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.12 |
2020 | $0.05 |
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way.
Worst Drawdowns
The table below displays the maximum drawdowns of the Franklin Genomic Advancements ETF. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Franklin Genomic Advancements ETF was 56.33%, occurring on Oct 30, 2023. The portfolio has not yet recovered.
The current Franklin Genomic Advancements ETF drawdown is 43.60%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
---|---|---|---|---|---|---|
-56.33% | Sep 8, 2021 | 540 | Oct 30, 2023 | — | — | — |
-27.15% | Mar 5, 2020 | 8 | Mar 16, 2020 | 25 | Apr 24, 2020 | 33 |
-26.01% | Feb 16, 2021 | 15 | Mar 8, 2021 | 101 | Jul 30, 2021 | 116 |
-8.87% | Sep 3, 2020 | 3 | Sep 8, 2020 | 19 | Oct 5, 2020 | 22 |
-8.02% | Oct 14, 2020 | 14 | Nov 2, 2020 | 3 | Nov 5, 2020 | 17 |
Volatility
Volatility Chart
The current Franklin Genomic Advancements ETF volatility is 3.35%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.